Study
How do the HCP profiles compare
between commercial mAbs?
with Rikke Lund, Alphalyse
Have you ever wondered if there are still trace amounts of problematic host cell proteins (HCPs) - or other process-related impurities - in marketed antibody drugs?
Or, just how similar the HCP profile of a mAb biosimilar is to the originator?
Using a unique mass spectrometry-based assay Alphalyse has analyzed and
compared HCPs in more than 50 mAbs. Some of these include Humira and Gazyvaro.
We now present the results from the study:
In this on-demand webinar Rikke Lund shares the study setup, analytical method,
and a list of the HCPs identified. She also highlights potentially problematic Host Cell Proteins
found in several of the monoclonal antibodies.
, ,